Guidelines for interstitial I-125 implants in prostate cancer;La curiethérapie prostatique par implantation permanente d'iode-125: Les règles de bonne conduite

Cancer/Radiotherapie

Volumn 6, Issue 2, 2002, Pages 112-115

  Chauveinc, L ^b   Salem, N ^a,b   Pommier, P ^a,b   Peiffert, D ^a,b   Guerif, S ^a,b   Hannoun Levy, J M ^a,b   Labib, A ^a,b   Delannes, M ^a,b   Hennequin, C ^a,b   Moncho, V ^a,b   Cosset, J M ^a,b   Mallet, F ^a,b   Flam, T ^a,b  

^a INSTITUT CURIE   (France)

^b NONE

Author keywords

Brachytherapy; External beam radiation; Iodine 125; Prostate carcinoma; Radical prostatectomy

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

CONFERENCE PAPER; DOSIMETRY; IMPLANT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION PROTECTION; RADIOISOTOPE THERAPY; TREATMENT INDICATION;

EID: 0036241248     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(02)00156-7     Document Type: Conference Paper

References (26)

1. Therapeutic options available for treating prostate cancer
2. Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the Karolinska series
3. Prostate seed implant quality assessment using MR and CT image fusion
4. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer
5. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma
6. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
7. Local staging of prostate cancer by endorectal MRI using fast spin-echo sequences: Prospective correlation with pathological findings after radical prostatectomy
8. Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer
9. Prostate brachytherapy: Increasing demand for the procedure despite the lack of standardized quality assurance and long term outcome data
10. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
11. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance
12. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early-stage prostate cancer
13. Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging
14. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer
15. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis
16. Radioisotopic implantation for carcinoma of the prostate: Does it work better than it used to?
17. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
18. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
19. Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer
20. Defining the risk of developing Grade 2 proctitis following (125) I prostate brachytherapy using a rectal dose-volume histogram analysis
21. A dose-response study for I-125 prostate implants
22. Transperineal ultrasound-guided radioactive seed implantation for organ- confined carcinoma of the prostate
23. Prostate brachytherapy: Treatment strategies
24. Brachytherapy for prostate cancer: Real-time three-dimensional interactive seed implantation
25. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate
26. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy